Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Erin L Schenk

TitleAsst Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone303/724-2980

    Collapse Biography 
    Collapse education and training
    Mayo Medical School, Rochester, MNM.D.05/2011
    Mayo Graduate Schoole, Rochester, MNPh.D.05/2011Immunology
    Mayo Clinic Internal Medicine Residence, Rochester, MN6/2014
    Mayo Clinic Hematology/Medical Oncology Fellowship, Rochester, MN3/2018
    Collapse awards and honors
    2017 - 2018IASLC Academy Award, IASLC
    2018Finalist, Immuno-Oncology Young Investigators Forum
    2018Outstanding Fellow Award, Highest Rated and Top Abstract, Minnesota Society of Clinical Oncology

    Collapse Overview 

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Schenk E, Boland J, Mansfield A, Aubry MC, Dietz A. Local and systemic immunity predict survival in patients with pulmonary sarcomatoid carcinoma. Med Oncol. 2017 Aug; 34(8):140. PMID: 28711968.
      View in: PubMed
    2. Schenk E, Hendrickson AE, Northfelt D, Toft DO, Ames MM, Menefee M, Satele D, Qin R, Erlichman C. Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies. Invest New Drugs. 2013 Oct; 31(5):1251-6. PMID: 23543109; PMCID: PMC3929968.
    3. Schenk EL, Koh BD, Flatten KS, Peterson KL, Parry D, Hess AD, Smith BD, Karp JE, Karnitz LM, Kaufmann SH. Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro. Clin Cancer Res. 2012 Oct 01; 18(19):5364-73. PMID: 22869869; PMCID: PMC3463653.
    4. Cabrera R, Schenk EL, Nava-Parada P, Bell MP, Van Keulen VP, Marler RJ, Felts SJ, Pease LR. Retraction: Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo. J Immunol. 2010 Jun 01; 184(11):6556. PMID: 20483796; PMCID: PMC3401068.
    5. Radhakrishnan S, Cabrera R, Schenk EL, Nava-Parada P, Bell MP, Van Keulen VP, Marler RJ, Felts SJ, Pease LR. Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo. J Immunol. 2008 Sep 01; 181(5):3137-47. PMID: 18713984; PMCID: PMC2582200.
    6. Heckman KL, Schenk EL, Radhakrishnan S, Pavelko KD, Hansen MJ, Pease LR. Fast-tracked CTL: rapid induction of potent anti-tumor killer T cells in situ. Eur J Immunol. 2007 Jul; 37(7):1827-35. PMID: 17549735.
      View in: PubMed
    7. Hildebrand WH, Turnquist HR, Prilliman KR, Hickman HD, Schenk EL, McIlhaney MM, Solheim JC. HLA class I polymorphism has a dual impact on ligand binding and chaperone interaction. Hum Immunol. 2002 Apr; 63(4):248-55. PMID: 12039406.
      View in: PubMed
    8. Turnquist HR, Schenk EL, McIlhaney MM, Hickman HD, Hildebrand WH, Solheim JC. Disparate binding of chaperone proteins by HLA-A subtypes. Immunogenetics. 2002 Feb; 53(10-11):830-4. PMID: 11862383.
      View in: PubMed
    9. Turnquist HR, Vargas SE, Schenk EL, McIlhaney MM, Reber AJ, Solheim JC. The interface between tapasin and MHC class I: identification of amino acid residues in both proteins that influence their interaction. Immunol Res. 2002; 25(3):261-9. PMID: 12018464.
      View in: PubMed
    Schenk's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)